Trial Profile
Overcoming Barriers to Vaccination With GARDASIL in Underserved Girls and Adolescents.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Therapeutic Use
- 08 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Nov 2013 Planned end date changed from 1 Jun 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 03 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.